SBIR/STTR Research Award

Antiepileptic Neurotoxicity Test

Award identifier 8fdd2351560e3efc3752d68da788bf7548240b4a292b4cb99e76396e00efcabdAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$0

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SAM TECHNOLOGY, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Patients with epilepsy often suffer from cognitive impairments. Seizure control can improve cognitive status; yet the anti-epileptic drugs (AEDs) often used for this purpose can themselves affect mental function. Thus, defining an effective treatment for an individual patient often requires balancing seizure control with potential medication side effects. While efficacy for seizure control is relatively easy for the clinician to gauge, currently there is no efficient objective measure of brain function used to assess changes in cognitive status during treatment. We propose to develop a specialized system, the Ant epileptic Neurotoxicity Test (ANT), to address this need. Our prior research suggests that sensitive indices of attention and memory can be derived from multivariate combinations of EEG, ERP and behavioral performance measures. During Phase I we demonstrated that such methods are sensitive to both acute dosing with older generation medications, and to the cognitive side effects of chronic dosing with newer AEDs. Progress was also made on the design and implementation of an automated clinical testing system that the ANT would be based on, and on defining modifications to signal processing algorithms to accommodate abnormal EEGs. In Phase II our methods will be extended and a prototype ANT will be implemented and validated in collaborative studies with epilepsy specialists. A resulting first generation ANT will enable research on the neurocognitive changes associated with epilepsy treatments, providing an efficient, standardized means to measure cognitive brain function across different laboratories and clinics. With refinement, the system could improve patient care, for example by helping a physician to select the best drug and dose level for an individual patient. There is a significant market demand for such a device in the context of epileptology, and related products could find widespread use as assessment tools in many areas of neurology and psychiatry.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.